Literature DB >> 35396676

Interactions with the CYP3A inhibitor voriconazole differ between extended-LCP- and immediate-release tacrolimus formulations.

Gerold Thölking1,2, Ulrich Jehn2, Stefan Reuter3.   

Abstract

Entities:  

Year:  2022        PMID： 35396676     DOI： 10.1007/s12185-022-03350-8

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  3 in total

1.  Prolonged-Release Tacrolimus Is Less Susceptible to Interaction With the Strong CYP3A Inhibitor Voriconazole in Healthy Volunteers.

Authors:  Andrea Huppertz; Christian Ott; Thomas Bruckner; Kathrin I Foerster; Jürgen Burhenne; Johanna Weiss; Markus Zorn; Walter E Haefeli; David Czock
Journal:  Clin Pharmacol Ther       Date:  2019-07-10       Impact factor: 6.875

Review 2.  Tacrolimus - Pharmacokinetic Considerations for Clinicians.

Authors:  Katharina Schutte-Nutgen; Gerold Tholking; Barbara Suwelack; Stefan Reuter
Journal:  Curr Drug Metab       Date:  2018       Impact factor: 3.731

3.  Differences in kinetics of tacrolimus concentration after letermovir discontinuation by type of concomitant azole antifungal.

Authors:  Toshihisa Nakashima; Yoshihiro Inamoto; Jun Aoki; Ayumu Ito; Takashi Tanaka; Sung-Won Kim; Hironobu Hashimoto; Takahiro Fukuda; Tetsuya Furukawa
Journal:  Int J Hematol       Date:  2022-01-28       Impact factor: 2.490
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.